The Vitek Gram-Positive Susceptibility Card (GPS) and Gram-Negative General Susceptibility Plus Card (GSC Plus) were tested on the AutoMicrobic System (AMS) 50 times each with the recommended control organisms. Only 1 drug (chloramphenicol) of 11 on the GPS and 1 (gentamicin) of 10 on the GSC Plus could be adequately controlled, leaving unsubstantiated the results obtained with patient isolates on Table  2 ]) on the GSC Plus could be controlled 95% of the time or more. The remaining 10 drugs on the GPS could not be controlled on any day tested, whereas the other 9 drugs on the GSC Plus resulted in acceptable on-scale endpoints less than 95% of the time.
The National Committee for Clinical Laboratory Standards has consistently indicated, as they have in their most recent standard (3) , that for each antimicrobial agent tested to determine a MIC endpoint, at least one control strain should provide on-scale endpoints, plus or minus one twofold dilution from the known modal value. The ideal control strain should have MIC endpoints near the middle of the range of drug concentrations tested. For each antimicrobial agent, 95% of the MICs obtained should be within ± one dilution of the modal MIC (1) . Batches of test panels in which the control MIC responses fall outside of the expected ranges are to be rejected after confirmation of the problem (1, 3) . The stated objectives of efficient control procedures are to monitor the precision and accuracy of the test procedure, the performance of reagents, and the performance of individuals involved with the technology (3) .
( Table  2 ]) on the GSC Plus could be controlled 95% of the time or more. The remaining 10 drugs on the GPS could not be controlled on any day tested, whereas the other 9 drugs on the GSC Plus resulted in acceptable on-scale endpoints less than 95% of the time.
The use of two control strains with the 11 GPS antimicrobial agents provided 22 drug response endpoints. Of these, only two (those for chloramphenicol) included a range of three consecutive, on-scale doubling dilutions (Table 1) With cephalothin, clindamycin, gentamicin, tetracycline, and vancomycin, the Streptococcus faecalis control responses also covered too broad a range of twofold dilutions, whereas the Staphylococcus aureus responses were less than or equal to the lowest concentration reported (cephalothin, clindamycin, and tetracycline) or covered too broad a range (gentamicin and vancomycin). For erythromycin, nitrofurantoin, and oxacillin, the Staphylococcus aureus responses were each less than or equal to the lowest concentration reported, whereas Streptococcus faecalis responses covered too broad a range (erythromycin), were at the low end of the range (nitrofurantoin), or were not supplied by Vitek in the GPS instructions (oxacillin).
The use of two control strains on the 10 GSC Plus antimicrobial agents provided 20 drug response endpoints. Of these, only four (E. coli versus ampicillin, cephalothin, and chloramphenicol; P. aeruginosa versus gentamicin) included a range of three consecutive, on-scale twofold dilutions (Table 2) . Eight Vitek-predicted endpoint ranges were provided as two or three twofold dilutions, the lowest concentration of which was also the lowest concentration reported for the drug and therefore not a precise endpoint. For ampicillin, cefamandole, cefoxitin, cephalothin, chloramphenicol, and tetracycline, the Vitek-predicted GSC Plus responses for the P. aeruginosa control strain were off-scale high, whereas the desired responses indicating on-scale, within-range endpoints for E. coli were achieved less than 95% of the time (ampicillin, cefoxitin, cephalothin, chloramphenicol, and tetracycline), or the E. coli response was less than or equal to the lowest concentration reported (cefamandole). For amikacin, carbenicillin, and tobramycin, acceptable responses for P. aeruginosa were achieved less than 95% of the time (although they were very close with tobramycin), whereas those for E. coli were never achieved (amikacin), were less than or equal to the lowest concentration reported (carbenicillin), or also were obtained less than 95% of the time (tobramycin).
The GPS card currently available has been improved to the point that there are on-scale endpoints (± one dilution) with at least one control organism for 5 of the 11 drugs. The Gram-Negative Susceptibility Card which replaced the GSC Plus Card used in this study has control deficiencies identical to those reported here. In addition, the control endpoints for trimethoprim-sulfa (which has been added to the Gram-Neg- 
